Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2022-04-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized report on non-operating fund occupation and other related party fund transactions for the year 2021 by Kuaihua Pharmaceutical Group Co., Ltd. It references an audit report issued on April 21, 2022, and includes detailed financial data related to fund usage and related party transactions. The document is titled as a "special report" and contains audited financial data and reconciliations with the audited financial statements. It is not a full annual report (10-K), nor is it a general audit report (AR) since it focuses specifically on related party fund transactions as required by regulatory guidelines. The document is not an announcement or a certification but a substantive report with financial data. Given the nature of the content and the focus on audit and regulatory compliance regarding fund occupation and related party transactions, this fits best under Audit Report / Information (AR). The document length is 2719 characters, which is sufficient for a detailed report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2021
2022-04-21 Chinese
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of the company 葵花药业集团股份有限公司. It includes information about the meeting date, time, location, voting procedures (both in-person and online), agenda items to be discussed and voted on, and instructions for shareholders on how to participate and vote. The document also contains an authorization proxy form for shareholders who cannot attend in person. The content is focused on informing shareholders about the AGM logistics and agenda, rather than presenting the actual annual report or financial statements. The document length is about 4831 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2022-04-21 Chinese
2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2021 Annual Report Summary" of 葵花药业集团股份有限公司, which clearly indicates it is a summary of the company's annual report for the fiscal year 2021. It contains detailed financial data including total assets, net profit, earnings per share, and quarterly financial data, as well as information about shareholders and company business overview. The length of the document is substantial (15,000 characters), and it includes comprehensive financial and operational information typical of an annual report. There is no indication that this is merely an announcement or a certification related to the report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-21 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2021 年年度报告全文" which translates to "2021 Annual Report Full Text" for 葵花药业集团股份有限公司 (Sunflower Pharmaceutical Group Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management analysis, and comprehensive company information for the fiscal year 2021. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-21 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 10th meeting of the 4th Supervisory Board of the company. It includes voting results on various reports and proposals related to the 2021 annual report, financial statements, profit distribution, internal control evaluation, and other operational matters. The document does not contain the full annual report or financial statements themselves but rather the supervisory board's approval and recommendation to submit these reports to the shareholders' meeting. The document length is short (1988 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory announcement of supervisory board meeting resolutions and approvals.
2022-04-21 Chinese
关于参与认购基金份额的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by a company about its participation in subscribing to fund shares, including extensive information about the fund, partners, investment purpose, and risk disclosures. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or a report publication announcement. The content focuses on a capital investment activity by the company using its own funds to subscribe to a private equity fund. This fits the definition of a Capital/Financing Update, which covers updates on company fundraising, financing activities, or capital structure changes.
2022-04-11 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.